Synthesis of three novel curcumin analog compounds and their activity tests against breast cancer based on in vitro, network pharmacology, and molecular docking assessments

View Full Paper

Ask AI

Bookmark

Authors

Discussion

In vitro assessment demonstrated cytotoxic activity of curcumin analogs, highlighting potential targets in breast cancer pathways.

Compound B exhibited the highest anticancer activity against T47D and HER2 cells, with specific IC50 values.
Aldol condensation was used to produce novel curcumin analogs, which showed improved pharmacokinetic profiles compared to curcumin.
Molecular docking revealed mitogen-activated protein kinase 8 as the main target of compound A, indicating specific action pathways.
Limited oral bioavailability was noted, suggesting further optimization of compounds is necessary for therapeutic applications.

Astuti et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark